OnKure Therapeutics reports that Trails Edge-related filers beneficially own 2,409,638 shares (6.0% of Class A Common Stock) as of March 31, 2026. The filing states those shares are held directly by Trails Edge Biotechnology and that Trails Edge Capital and Ortav Yehudai may be deemed beneficial owners by virtue of management and voting discretion. Ownership percentages are calculated from approximately 40,387,201 shares issued and outstanding as of the Event Date, reflecting 13,673,565 shares outstanding as of March 11, 2026 and 26,713,636 shares issued in a private placement on March 31, 2026. The report is a joint Schedule 13G, and signatures and a Joint Filing Agreement are included.
Positive
None.
Negative
None.
Insights
Trails Edge reports a passive, 6.0% stake in OnKure following an issuer private placement.
Trails Edge Biotechnology holds 2,409,638 shares, representing 6.0% of the issuer's stated 40,387,201 shares outstanding as of March 31, 2026. The filing attributes beneficial ownership to related manager and CIO roles due to voting and investment discretion.
Key dependencies include the issuer's reported outstanding share counts and the private placement that increased shares by 26,713,636. Subsequent filings could change percentages if additional issuances or transfers occur; cash‑flow treatment is not stated in the excerpt.
Key Figures
Shares held by Trails Edge Biotechnology:2,409,638 sharesPercent of class:6.0%Shares outstanding (denominator):40,387,201 shares+2 more
5 metrics
Shares held by Trails Edge Biotechnology2,409,638 sharesheld directly as of <date>March 31, 2026</date>
Percent of class6.0%percentage of Class A Common Stock as of <date>March 31, 2026</date>
Shares outstanding (denominator)40,387,201 sharesaggregate outstanding used to compute percentage as of <date>March 31, 2026</date>
Shares outstanding reported March 11, 202613,673,565 sharesreported in issuer's Annual Report on Form 10-K
Private placement shares26,713,636 sharesissued in connection with private placement on <date>March 31, 2026</date>
"As of March 31, 2026 the Filers may be deemed to beneficially own 2,409,638 shares"
Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.
Event Dateother
"As of March 31, 2026 (the "Event Date") each Filer may be deemed to beneficially own"
private placementmarket
"26,713,636 shares of Common Stock issued in connection with the Issuer's private placement on the Event Date"
A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.
What stake does Trails Edge report in OnKure (OKUR)?
Trails Edge-related filers report beneficial ownership of 2,409,638 shares, representing 6.0% of OnKure's Class A Common Stock as of March 31, 2026. The shares are held directly by Trails Edge Biotechnology.
How was the 6.0% ownership percentage calculated for OKUR?
The percentage uses a denominator of 40,387,201 shares outstanding as of March 31, 2026, combining 13,673,565 shares reported as of March 11, 2026 and 26,713,636 shares issued in a private placement on the Event Date.
Who are the filers reporting the OKUR holdings?
Trails Edge Capital Partners, LP, Trails Edge Biotechnology Master Fund, LP, and Ortav Yehudai filed jointly. Trails Edge Capital is manager to the fund and Mr. Yehudai is the Chief Investment Officer, per the filing.
Are the reported shares directly held or managed indirectly for OKUR?
The filing states the 2,409,638 shares are held directly by Trails Edge Biotechnology. Trails Edge Capital and Mr. Yehudai may be deemed beneficial owners due to managerial and voting discretion.
Does the Schedule 13G indicate any change in ownership method for OKUR?
The Schedule 13G is a joint filing reporting beneficial ownership; it lists signatures and a Joint Filing Agreement but does not state a change in ownership method or any transactional terms in this excerpt.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
OnKure Therapeutics, Inc.
(Name of Issuer)
Class A Common Stock, $0.0001 par value per share
(Title of Class of Securities)
68277Q105
(CUSIP Number)
03/31/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
68277Q105
1
Names of Reporting Persons
Trails Edge Capital Partners, LP
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
2,409,638.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
2,409,638.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
2,409,638.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
6.0 %
12
Type of Reporting Person (See Instructions)
IA, PN
Comment for Type of Reporting Person: See Item 4 for additional information.
SCHEDULE 13G
CUSIP Number(s):
68277Q105
1
Names of Reporting Persons
Trails Edge Biotechnology Master Fund, LP
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
CAYMAN ISLANDS
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
2,409,638.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
2,409,638.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
2,409,638.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
6.0 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: See Item 4 for additional information.
SCHEDULE 13G
CUSIP Number(s):
68277Q105
1
Names of Reporting Persons
Ortav Yehudai
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
2,409,638.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
2,409,638.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
2,409,638.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
6.0 %
12
Type of Reporting Person (See Instructions)
IN
Comment for Type of Reporting Person: See Item 4 for additional information.
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
OnKure Therapeutics, Inc.
(b)
Address of issuer's principal executive offices:
6707 Winchester Circle, #400, Boulder, CO, 80301
Item 2.
(a)
Name of person filing:
This report on Schedule 13G is being filed by Trails Edge Capital Partners, LP, a Delaware limited partnership ("Trails Edge Capital"), Trails Edge Biotechnology Master Fund, LP, a Cayman Islands limited partnership ("Trails Edge Biotechnology"), and Ortav Yehudai ("Mr. Yehudai"). Trails Edge Capital is the investment manager to Trails Edge Biotechnology, and Mr. Yehudai is the Chief Investment Officer of Trails Edge Capital. Each of Trails Edge Capital, Trails Edge Biotechnology and Mr. Yehudai are referred to individually as a "Filer" and collectively as the "Filers".
(b)
Address or principal business office or, if none, residence:
The address for each Filer is 3455 Peachtree Road NE, 5th Floor, Atlanta, GA 30326.
(c)
Citizenship:
See Item 4 of the cover page of each Filer.
(d)
Title of class of securities:
Class A Common Stock, $0.0001 par value per share
(e)
CUSIP Number(s):
68277Q105
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
As of March 31, 2026 (the "Event Date"), each Filer may be deemed to beneficially own an aggregate of 2,409,638 shares (the "Shares") of Class A Common Stock, $0.0001 par value per share (the "Common Stock"), of OnKure Therapeutics, Inc. (the "Issuer"). The 2,409,638 Shares reported as beneficially owned on this Schedule 13G by each Filer consist of 2,409,638 Shares held directly by Trails Edge Biotechnology. As a result, Trails Edge Biotechnology beneficially owns 6.0% of the outstanding Shares of the Issuer as of the Event Date. Trails Edge Capital, as the investment manager to Trails Edge Biotechnology, may be deemed to beneficially own these securities. Mr. Yehudai, as the Chief Investment Officer of Trails Edge Capital, exercises voting and investment discretion with respect to these securities and as such may be deemed to beneficially own 6.0% of the outstanding Shares of the Issuer as of the Event Date.
Ownership percentages are based on approximately 40,387,201 shares of Common Stock issued and outstanding as of the Event Date, consisting of (i) 13,673,565 shares of Common Stock issued and outstanding as of March 11, 2026 as reported by the Issuer in its Annual Report on Form 10-K for the year ended December 31, 2025 filed with the Securities and Exchange Commission ("SEC") on March 12, 2026, and (ii) 26,713,636 shares of Common Stock issued in connection with the Issuer's private placement on the Event Date as reported by the Issuer in its Current Report on Form 8-K filed with the SEC on March 30, 2026.
(b)
Percent of class:
6.0%
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
2,409,638.00
(ii) Shared power to vote or to direct the vote:
0.00
(iii) Sole power to dispose or to direct the disposition of:
2,409,638.00
(iv) Shared power to dispose or to direct the disposition of:
0.00
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Trails Edge Capital Partners, LP
Signature:
/s/ Trails Edge Capital Partners, LLC, GP of Trails Edge Capital Partners, LP /s/ Ortav Yehudai
Name/Title:
Ortav Yehudai / Chief Investment Officer of Trails Edge Capital Partners, LLC
Date:
04/07/2026
Trails Edge Biotechnology Master Fund, LP
Signature:
/s/ Trails Edge GP, LLC, GP of Trails Edge Biotechnology Fund GP, LP, GP of Trails Edge Biotechnology Master Fund, LP /s/ Ortav Yehudai
